Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up.

Autor:	Adlany YK; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland., Šošić L; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland., Senti G; University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland., Lang CCV; Department of Dermatology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland., Wüthrich B; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland., Kündig TM; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland.; Department of Dermatology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland., Johansen P; Department of Dermatology, University of Zurich, Raemistrasse 100, Zurich, Switzerland.; Department of Dermatology, University Hospital Zurich, Raemistrasse 100, Zurich, Switzerland.
Jazyk:	angličtina
Zdroj:	The journal of allergy and clinical immunology. Global [J Allergy Clin Immunol Glob] 2022 Oct 27; Vol. 2 (1), pp. 43-50. Date of Electronic Publication: 2022 Oct 27 (Print Publication: 2023).
DOI:	10.1016/j.jacig.2022.09.007
Abstrakt:	Background: In 2002-2005, we conducted a phase I/II clinical trial where a new allergy immunotherapy (AIT) route was introduced: intralymphatic immunotherapy (ILIT). Ultrasound guidance allowed injection of allergen directly into inguinal lymph nodes. Grass pollen-allergic patients received 3 injections with 1-month intervals. The short ILIT was more patient-friendly, required lower dosing, and was comparable with SCIT regarding short-term efficacy, which was used as a reference. Objective: Nineteen years after ILIT, the same patients were followed up to assess the long-term effect on quality of life and efficacy of the treatment. Methods: Patients who received ILIT and SCIT in 2002-2005 and an additional group of patients, who completed SCIT in 2015-2018, were recruited. All participants received a trial-specific in-house questionnaire and a standardized Rhinoconjunctivitis Quality of Life Questionnaire. Data were recorded off- (February 2021) and on- (May-June 2021) season. Descriptive statistics were applied. Results: Of 58 and 54 patients who originally received ILIT or SCIT, 25 (43%) and 29 (54%) patients, respectively, returned the questionnaires for analysis. Four (16%) and 3 (11%) of the ILIT and SCIT patients, respectively, developed complete protection against grass pollen-mediated rhinitis, whereas another 15 (60%) and 20 (69%) expressed satisfaction with the received AIT. In both groups, any persistent symptoms were reported as mild. Medication usage in the ILIT and SCIT groups was comparable. Nineteen (76%) and 23 (79%) patients, respectively, expressed satisfaction with their AIT. Conclusions: Grass pollen ILIT leads to long-term significant improvement in rhinitis-associated quality of life 19 years after treatment, and the ILIT quality-of-life effect was not inferior to that of SCIT. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu